Cas No.: | 2095161-11-6 |
Chemical Name: | EPZ031686 |
Synonyms: | 6-Chloro-2,3-dihydro-2-oxo-N-[(3-endo)-8-[[[1-(4,4,4-trifluorobutyl)-4-piperidinyl]methyl]sulfonyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-indole-5-carboxamide;EPZ031686 |
SMILES: | ClC1C(C(=O)N[C@H]2C[C@@H]3N(S(=O)(=O)CC4CCN(CCCC(F)(F)F)CC4)[C@H](C2)CC3)=CC2CC(NC=2C=1)=O |
Formula: | C26H34ClF3N4O4S |
M.Wt: | 591.09 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | EPZ031686 is a noncompetitive inhibitor for SMYD3 and MEKK2 with a Ki=1.2 and 1.1 nM respectively. In vitro: EPZ031686 have a cellular potency at a level sufficient to probe the in vitro biology of SMYD3 inhibition. The first SMYD3 inhibitor identify to show double-digit nanomolar cellular activity. EPZ031686 show < 30% inhibition against 16 histone methyltransferase targets at a 10 uM screening concentration. In vivo: EPZ031686 show good bioavailability following oral dosing in mice. The administration for mice is 1 mg/kg by i.v. |